Decitabine,Cytarabine(Ara-C) and Arsenic Trioxide(ATO) in the Treatment of Acute Myeloid Leukemia With p53 Mutations

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT03381781

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:36:42.928554+00:00

Published At

2018-01-04T00:00:00+00:00

Record Updated At

2018-01-04

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Acute Myeloid Leukemia", "P53 Mutation"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2018-01-04"

protocolSection.identificationModule.nctId

"NCT03381781"

protocolSection.identificationModule.officialTitle

"Decitabine,Cytarabine(Ara-C) and Arsenic Trioxide(ATO) in the Treatment of Acute Myeloid Leukemia With p53 Mutations"

protocolSection.statusModule.overallStatus

"UNKNOWN"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
• P53 Mutation (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.